Glaxo Augments OTCs With Stiefel Deal, Gains Strong Dermatology Foothold
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline will more than double its dermatology sales to $1.5 billion by acquiring Stiefel Laboratories and creating a global specialist business across Rx and OTC drugs